Results 51 to 60 of about 74,631 (338)

Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease

eNeurologicalSci, 2018
We conducted a phase I study investigating the efficacy, safety, and tolerability of ONO-2160, a newly developed levodopa pro-drug, and carbidopa compared with levodopa and carbidopa to stabilize levodopa plasma concentration fluctuations in Japanese ...
Masahiro Nomoto, Masahiro Nagai, Noriko Nishikawa, Rina Ando, Yoshifumi Kagamiishi, Koji Yano, Shigeto Saito, Atsushi Takeda   +7 more
doaj   +1 more source

Acting without being in control: Exploring volition in Parkinson's disease with impulsive compulsive behaviours. [PDF]

, 2017
BACKGROUND: Several aspects of volitional control of action may be relevant in the pathophysiology of impulsive-compulsive behaviours (ICB) in Parkinson's disease (PD).
de Boer, L, Edwards, MJ, Haggard, P, Morgante, F, Ricciardi, L, Sorbera, C, Stenner, M-P   +6 more
core   +2 more sources

Rewiring Neuroimmunity: Nanoplatform Innovations for CNS Disease Therapy

Advanced Therapeutics, EarlyView.
This review explores emerging nanoplatform strategies designed to modulate neuroimmune responses for treating central nervous system (CNS) disorders. It examines structural and microenvironmental barriers, advances in multifunctional and targeted nanotechnologies, and highlights clinical progress and translational challenges, offering insights into the
Muhammad Usman Akbar, Weiwei Guo, Xin Shen, Yimeng Fang, Yilin Liu, Peng‐Yuan Wang, Roey Elnathan, Yaping Chen   +7 more
wiley   +1 more source

DOPAMINE DYSREGULATION SYNDROME IN PARKINSON’S DISEASE AND APPROACHES TO ITS CORRECTION WITH DRUGS

Klinicist, 2017
The objective is to describe a clinical case of dopamine dysregulation syndrome (DDS) with compulsive intake of large doses of levodopa in a patient with Parkinson’s disease (PD).Materials and methods. Male patient R., born in 1956, has had PD since 2004
S. M. Omarova, N. V. Fedorova
doaj   +1 more source

The impact of motor symptoms on self-reported anxiety in Parkinson's disease [PDF]

, 2017
OBJECTIVE: Anxiety is commonly endorsed in Parkinson's disease (PD) and significantly affects quality of life. The Beck Anxiety Inventory (BAI) is often used but contains items that overlap with common PD motor symptoms (e.g., “hands trembling”). Because
Cronin-Golomb, A., Le, A. M., Neargarder, S., Salazar, R. D.   +3 more
core   +1 more source

Dopamine D1 Receptor Contributes to Glucocorticoid‐Associated Osteonecrosis of Femoral Head Protection Through the ATF3/CHOP Axis to Inhibit Osteoblastic Apoptosis

Advanced Science, EarlyView.
This work identifies a novel mechanism by which dopamine D1 receptor (DRD1) contributes to the pathogenesis of glucocorticoid (GC)‐associated osteonecrosis of the femoral head (ONFH) through the regulation of osteoblastic apoptosis, indicating that DRD1 serves as a critical mediator of the crosstalk between the nervous and skeletal systems.
Kai Zheng, Wenming Li, Tianhao Wang, Gaoran Ge, Wei Zhang, Yi Qin, Wenhao Li, Zebin Wu, Zhen Wang, Gang Rui, Yaozeng Xu, Dechun Geng   +11 more
wiley   +1 more source

Management of rapid eye movement sleep behavior disorder in patients with Parkinson's disease [PDF]

, 2016
Among all of the devastating effects that Parkinson’s disease (PD) has on an individual, sleep dysfunction is one that can have a profound effect on the entire family of the patient. The most potentially destructive of these sleep syndromes being that of
Jeffries, Michael
core   +1 more source

Cistanche tubulosa improves peripheral neuropathy in MPTP‐induced PD mice based on regulation of m6A methylation

Animal Models and Experimental Medicine, EarlyView.
At steady state, DRG ensures low‐level expression of TH+ neurons under the protection of AKT. However, the DRG level of PD mouse model under MPTP toxicity increased significantly, and the expression of IL‐6 and CASP3 increased. This process was accompanied by the occurrence of m6A demethylation, with a significant increase in FTO as the main ...
Yatan Li, Wei Jia, Junhua Hu, Borui Zhang, Xinxin Qi, Jianhua Yang, Xinling Yang   +6 more
wiley   +1 more source

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective

Neuropsychiatric Disease and Treatment, 2008
David J BrooksDivision of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UKAbstract: After 40 years of clinical experience, levodopa remains the gold standard treatment for Parkinson’s disease (PD) despite ...
David J Brooks
doaj  

Rasagiline as Adjunct to Levodopa for Treatment of Parkinson’s Disease: A Systematic Review and Meta-Analysis

Parkinson's Disease, 2022
Background. Rasagiline is a selective, irreversible monoamine oxidase type B inhibitor used as monotherapy in early Parkinson’s disease and as an adjunct therapy to levodopa in Parkinson’s disease with motor fluctuations. Objectives.
Osamu Kano, Hiroshi Tsuda, Ayako Hayashi, Masaki Arai   +3 more
doaj   +1 more source